Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RushNet, Inc. (RSHN) Announces No Reverse Stock Split, Abandonment of StopDrops Inc.
"There will be no reverse stock split. That has been abandoned."
https://www.globenewswire.com/news-release/2020/03/30/2008415/0/en/RushNet-Inc-RSHN-Announces-No-Reverse-Stock-Split-Abandonment-of-StopDrops-Inc.html
GB Sciences Files Provisional Patent Application for the Treatment of COVID-19-Related Acute Respiratory Distress Syndrome (ARDS), the Leading Cause of Hospitalization and Deaths, Utilizing Its Cannabinoid Containing Complex Mixtures (CCCM(TM))
9:00 AM ET 8/26/20 | Dow Jones
LAS VEGAS, NV / ACCESSWIRE / August 26, 2020 / GB Sciences, Inc. (OTCQB:GBLX) has filed a provisional patent application, assigned to GBS Global Biopharma (GBS), Inc., for the use of its new proprietary cannabinoid containing complex mixtures (CCCM(TM)) for the treatment of Cytokine Storm Syndromes (CSS), including acute respiratory distress syndrome (ARDS) in COVID-19 patients. CSS and ARDS are the leading cause of death in COVID-19. Based on data obtained from GBS's two-year study on the use of cannabis-based ingredients for modulating inflammatory processes within human immune cells, GBS's CCCM(TM) were designed to reduce levels of specific cytokines and pro-inflammatory processes triggered by SARS-CoV-2 infections, while preserving those immune functions and cytokines that are necessary for fighting the viral infection.
"Our CCCM(TM) are cannabis-based combination therapies designed to target key cytokines that correlate with symptom severity in COVID-19 patients and are known to cause Cytokine Storm Syndromes, which may lead to hospitalization or even death. However, treatment of virally induced Cytokine Storm Syndromes in COVID-19 patients may not be as simple as using a broadly immunosuppressive strategy because the production of specific pro-inflammatory cytokines may be crucial for immune defense against SARS-CoV-2 infections, or other viral infections in the future," explained Dr. Andrea Small-Howard, Chief Science Officer and Director of both GB Sciences, Inc. and GBS Global Biopharma, Inc. "GBS's CCCM(TM) are also being developed as an adjunctive therapy to be delivered to COVID-19 patients in combination with clinically (FDA)-approved Interferon products for the most beneficial patient results - reduced Cytokine Storm Syndrome while preserving the anti-viral immune processes necessary for fighting viral infections."
Inflammatory disorders represent a serious global health and economic burden with over $200 billion spent annually. The current COVID-19 pandemic has created an increased demand for novel anti-inflammatory treatments to combat the effects of the severe forms of COVID-19.
"These novel CCCM(TM) represent a much-needed alternative for the treatment of inflammatory disorders, including COVID-19 and many other serious conditions," said Dr. Michael Farley, President and Director of GBS Global Biopharma.
"This is a big deal. In plain English, our combinations of specific cannabinoids and terpenes were designed to quiet the immune system's storm without totally disabling the immune system," said John Poss, CEO and Chairman of GB Sciences.
In addition to this new provisional patent application, GBS's intellectual property portfolio currently contains four patents that are issued in the U.S. with corresponding patents issued internationally. Seven nonprovisional patent applications plus three provisional patent applications are pending in the U.S. and 29 patent applications have been filed internationally.
About GB Sciences, Inc. and GBS Global Biopharma, Inc.
GB Sciences, Inc. (OTCQB:GBLX), through its Canadian entity GBS Global Biopharma, Inc., is a dedicated biopharmaceutical research and cannabinoid-based drug development company whose goal is to create patented formulations for safe, standardized, cannabinoid therapies that target a variety of medical conditions in both the pharmaceutical and wellness markets.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Contact Information
GB Sciences, Inc.
3550 West Teco Avenue
Las Vegas, NV 89118
866-721-0297
GBS Global Biopharma, Inc.
200-900 Morrison Drive
Ottawa, Ontario K2H8K7
Michael Farley, Ph.D., President & Director
michael@gbsglobalbiopharma.com
SOURCE: GB Sciences, Inc.
View source version on accesswire.com:
https://www.accesswire.com/603407/GB-Sciences-Files-Provisional-Patent-Application-for-the-Treatment-of-COVID-19-Related-Acute-Respiratory-Distress-Syndrome-ARDS-the-Leading-Cause-of-Hospitalization-and-Deaths-Utilizing-Its-Cannabinoid-Containing-Complex-Mixtures-CCCMTM
> Dow Jones Newswires
August 26, 2020 09:00 ET (13:00 GMT)
Shakey, shakey, shakey!
RSHN
thx. JJ. Never left, just lurking in the background.
I've always liked the way she moves.
GRPS
Let them shake it, I need a cheaper entry. :)
My thoughts are they are smart business men and doctors and they know if they keep putting out PRs all the time they will be called pump and dumpers. SO they are not wasting their money on PRs. They are getting the negotiations done and we don't see it. It takes time and patience.
We will see.
$RSHN $GRPS
Amen! I believe, too.
Holy $h1T!!whats up IDGC?
I second that! All this hype about a PR just affects the SP negatively if it doesn't drop. It will happen when it happens.
RSHN
The majority of tickers here I can agree with what you're saying, Billy. However, lots of start ups that come to fruition use safe harbor laws. When I say we know, it's because the amount of due diligence a group of us have done on RSHN and also the fact that they are tied to legitimate companies with tangible products. Why would they associate themselves with a fake company which could ruin their reputation?
People are also paid to bash a stock, so it goes both ways. Playing any market is a risk. Pinks are riskier, that's why we have to do more homework.
RSHN!
That’s because we’re savvy and know the shenanigans being played here. But we’re not going away! We know what we own. Just because we’re not buying doesn’t mean we’re selling!!
Go RSHN!
yes, pure manipulation. They know peeps are waiting for SP to drop so they purposely sell lower to shake the tree. It's been happening for way too long here.
Go RSHN
Yep, not worried! Adding as I can.
RSHN
REALLY? I don't think a POS would reduce debts and liabilities for shareholders from $8,783,787 in 2018 way down to only $60,781 in 2019!
Learning to read a balance sheet is a good thing.
Go RSHN!
Well, my take is a huge positive difference in debts and liabilities for us shareholders from $ 8,783,787 in 2018 way down to only $60,781 in 2019!
Sure negative difference in net income, but also Operating expenses increased.
If anyone knows how to read balance sheets and looks at the historicals, then its clear to see progress is happening here. Sounds to me like they are making things happen with increased Operating expenses which will obviously affect net income...Increased net income will follow.
They increased OS by only 35 million. Those shares are restricted and valued at .002, for services rendered.
I think we still have lots to see coming. Looking forward to next fins. RSHN!
Thanks for the info, D-money! I’m so conflicted though. Not sure whether to believe these official filings with the SEC or if this is really a scam.
Hmmm, what a conundrum!
Go RSHN.
Team Rush!
So have a lot of other stocks in this sector. GBLX is not an anomaly.
Nice catch!
ABC news GB Sciences
https://abcnews.go.com/Health/wireStory/medical-marijuana-cleared-release-louisiana-patients-64723130
Damned if you do, damned if you don't. If they don't say anything shareholders get pissed, "no transparency". If they keep us posted then "they talk too much"...
Yep, look at the move she made with just 50 mil shares while in trips. That means lots of peeps holding on because they know what RSHN is capable of... Anyone selling for a flip here will lose eventually.
Imagine when we get tradings days 100 mil + like we used to, Anto.
To da MOON!!
It's holding steady. Went up a lil bit, but its summer in OTC and you know what happens.
Accumulation is off the charts though, so it will get its run. New SS makes it an OTC gem.
Didn't plummet though, at all.
Anyhow, my point was that the shares could be cancelled all together and removed from SS.
I think if anything, since manipulation will be halted because of CV's arrest, POTN should have a better chance of a rising SP now.
IMO
Another ticker cancelled approximately 99% of its issued and outstanding shares of Common from 17,500,000,000 (17.5 Billion) to 495,000,000 (495 Million) due to shares were deemed to have been improperly and illegally issued and the court has ordered them to be cancelled.
So anything could happen here at POTN!
Goulding was never mentioned in the undercover FBI agents report. If he was involved he would have been mentioned.
Not surprised, Ernie! They must have given those 3 billion shares out already then. Happened much sooner.
At least he's consistent! lol. Only 3 billion more shares to dilute before the inevitable RS and name change.
not my thing.
Also, I consider your statement an opinion. Looking at your post history I can see a blatant pattern/agenda
RSHN sister GRPS shareholder update.
So much for all you calling this "Goulding consortium" a scam should rethink your statements.
Legit company is a shareholder. Go RSHN GRPS!
Gold River Productions Inc, Inst Holders, 2Q 2019 (GRPS)
3:09 AM ET 7/19/19 | Dow Jones
The following table shows the largest shareholders in GOLD RIVER PRODUCTIONS INC COM (GRPS) for the quarter ended June 30, 2019, listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 06/30/2019
Institution Shares Shares % Last
Held Changed Held Report
IFP Advisors Inc. 30,000 30,000 0.003 03/31
http://ifpartners.com/
https://www.nasdaq.com/quotes/institutional-portfolio/ifp-advisors-inc-986677
13F data provided by: Factset Research Systems Inc.;
Please send questions to ownership@factset.com.
Copyright, Factset Research Systems, 2019. All Rights Reserved.
> Dow Jones Newswires
July 19, 2019 03:09 ET (07:09 GMT)
GRPS shareholder update. News for GRPS alone for all of you who want it. So much for all you calling this a scam as well.
Legit company is a shareholder. Go GRPS!
Gold River Productions Inc, Inst Holders, 2Q 2019 (GRPS)
3:09 AM ET 7/19/19 | Dow Jones
The following table shows the largest shareholders in GOLD RIVER PRODUCTIONS INC COM (GRPS) for the quarter ended June 30, 2019, listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 06/30/2019
Institution Shares Shares % Last
Held Changed Held Report
IFP Advisors Inc. 30,000 30,000 0.003 03/31
http://ifpartners.com/
https://www.nasdaq.com/quotes/institutional-portfolio/ifp-advisors-inc-986677
13F data provided by: Factset Research Systems Inc.;
Please send questions to ownership@factset.com.
Copyright, Factset Research Systems, 2019. All Rights Reserved.
> Dow Jones Newswires
July 19, 2019 03:09 ET (07:09 GMT)
News. GBLX files patent for chronic pain treatment
https://www.prnewswire.com/news-releases/gb-sciences-files-novel-patent-application-for-chronic-pain-treatments-based-on-proprietary-cannabis-derived-formulations-300885219.html
Yes, Bead. Right on the money!
IMO
Morning, Cash.
Says 1:3000 here
https://www.facebook.com/1405473799518663/posts/2468494759883223?s=1363672919&sfns=mo